NTHI - NASDAQ
Neonc Technologies Holdings, Inc.
$4.35
-4.2%Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
At a Glance
Live SnapshotNeonc Technologies Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Neonc Technologies Holdings, Inc. Cash Flow Statement
NTHI • NASDAQ
| Neonc Technologies Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-62.1M | -11.9M | -14.9M | -3M | -3.4M | |
36.5K | 245.9K | 0.0 | 0.0 | 0.0 | |
35.6M | 0.0 | 0.0 | 1.3M | 2.2M | |
4.1M | 6M | 11.3M | 206.9K | 103.9K | |
2.1M | 1.5M | 1.7M | 666.2K | 655.7K | |
-20.4M | -4.2M | -1.9M | -881.7K | -396.7K | |
INVESTING ACTIVITIES | |||||
-500K | (0.0) | (0.0) | (0.0) | (0.0) | |
-500K | (0.0) | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||
17.2M | 4.6M | 450.0 | 2.4M | 0.0 | |
3.7M | 101K | 1.4M | -210K | 250K | |
0.0 | -469.8K | -94.6K | -700K | 0.0 | |
20.9M | 4.2M | 1.3M | 1.5M | 250K | |
CASH FLOW SUMMARY | |||||
-6.2K | 33K | -601.4K | 608.3K | -146.7K | |
64.9K | 31.9K | 633.3K | 25K | 171.7K | |
58.7K | 64.9K | 31.9K | 633.3K | 25K | |
-20.9M | -4.2M | -1.9M | -881.7K | -396.7K |
SEC Filings
NTHI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | May 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
S-3 S-3 N/A | April 10, 2026 | April 10, 2026 | ||
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
S-3 S-3 N/A | April 02, 2026 | April 02, 2026 | ||
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your NTHI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.